Antitumor activity of a newly developed monoclonal antibody against ROR1 in ovarian cancer cells

作者：Zhengna Yin, Mengyun Gao, Sasa Chu, Yiping Su, Chunping Ye, Yiquan Wang, Zhuanqin Pan, Zhuming Wang, Huilin Zhang, Hua Tong, Jin Zhu · 发表于：Oncotarget · 年份：2017 · DOI：10.18632/oncotarget.21618 · 被引用次数：21 · 研究领域：Cytokine Signaling Pathways and Interactions、PI3K/AKT/mTOR signaling in cancer、Cancer Cells and Metastasis

// Zhengna Yin 1, * , Mengyun Gao 1, * , Sasa Chu 2 , Yiping Su 1 , Chunping Ye 1 , Yiquan Wang 3 , Zhuanqin Pan 4 , Zhuming Wang 5 , Huilin Zhang 1 , Hua Tong 1 and Jin Zhu 6 1 Department of Obstetrics and Gynecology, Nanjing Maternity and Child Health Care Hospital, Obstetrics and Gynecology Hospital Affiliated to Nanjing Medical University, Nanjing 210004, China 2 Department of Infectious Disease, Institute of Liver Disease, Nanjing Jingdu Hospital, Nanjing 210002, China 3 Department of Traditional Chinese Internal Medicine, Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200071, China 4 Department of Nursing, Gaoyou People’s Hospital, Yangzhou 225600, China 5 Department of Pathology, Chinese Ministry of Health-designated Key Laboratory of Antibody Technology, Nanjing Medical University, Nanjing 210029, China 6 Huadong Medical Institute of Biotechniques, Nanjing 210002, China * These authors have contributed equally to this work Correspondence to: Hua Tong, email: thua8@163.com Huilin Zhang, email: zhl068@163.com Keywords: ROR1, monoclonal antibody production, chimeric antibody Fab, binding affinity, antitumor activity Received: July 12, 2017     Accepted: August 29, 2017     Published: October 07, 2017 ABSTRACT Receptor-tyrosine-kinase-like Orphan Receptor 1 (ROR1) is a tyrosine-protein kinase transmembrane receptor and ROR1 overexpression is associated with a poor prognosis in vari...